EUROAPI Launches Med4Cure Project to Boost Pharmaceutical Innovation
EUROAPI has officially announced the launch of its innovation programs under the Med4Cure project, supported by the European Union, to promote pharmaceutical sovereignty.
According to the press release, in June 2024, EUROAPI was selected among 13 European companies to receive public funding of up to one billion euros. In France, the government signed a contractual agreement with EUROAPI in July 2025, providing financial support up to 140 million euros as part of the France 2030 plan, to support the company's innovation initiatives.
Collaborative Efforts with Specialized Partners
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The Med4Cure project, officially launched at the Vertolaye site, involves a wide range of partners, including specialized startups and academic institutions. EUROAPI plans to collaborate with companies such as Abolis, Alysophil, and Crysttal, as well as renowned academic establishments, to enhance the sustainable production of active pharmaceutical ingredients in Europe.
Strategic Focus Areas of the Med4Cure Project
The Med4Cure project focuses on three strategic areas: the development of corticosteroids at the Vertolaye site, improving the bioavailability of nanocrystals, and relocating the production of macrolide antibiotics to Saint-Aubin-lès-Elbeuf. According to the company, these initiatives aim to strengthen competitive and sustainable production of active ingredients to meet European health needs.
Related
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 356,5 millions d'euros
Quarterly revenue: 356,5 millions d'euros
Revenue growth: -13,5 %
EBITDA: -43,1 millions d'euros
EBITDA margin: -12,1 %
Net income: -141,5 millions d'euros
Free cash flow: -103,4 millions d'euros
37,9 millions d'euros
Risks mentioned
Appréciation du forint hongrois pesant environ -9 M€ sur le Core EBITDA 2026
Baisse de la demande client à moyen terme sur certaines petites molécules produites à Francfort
Recul de 36,2 % des ventes API Solutions à Sanofi, forte dépendance client
Opportunities identified
Cession du site de Brindisi à Huvepharma, déficitaire de -11,0 M€ de Core EBITDA au S1 2026
Charges de personnel liées à FOCUS-27 attendues nettement plus faibles au S2 2026
Croissance de 11,5 % des ventes CMO en phase commerciale, à 107,6 M€
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
